ISOC1: Key Regulator of Cell Division and Signaling Pathways (G51015)

Target Name: ISOC1

NCBI ID: G51015

ISOC1

Other Name(s): Isochorismatase domain-containing protein 1 | isochorismatase domain containing 1 | Isochorismatase domain containing 1 | ISOC1_HUMAN | CGI-111

ISOC1: Key Regulator of Cell Division and Signaling Pathways

ISOC1 (Isochorismatase domain-containing protein 1) is a protein that is expressed in various tissues throughout the body. It is a key regulator of cell division and has been implicated in the development and progression of various diseases, including cancer.

One of the key functions of ISOC1 is its role in cell division. ISOC1 is a transcription factor that regulates the expression of genes involved in cell division, such as the factors that control the mitotic spindle formation that leads to cell division. ISOC1 has been shown to play a crucial role in the regulation of mitosis, the process by which a cell divides, as well as apoptosis, the process by which a cell undergoes programmed cell death.

In addition to its role in cell division, ISOC1 has also been shown to play a key role in the regulation of cell signaling pathways. ISOC1 has been shown to interact with various signaling molecules, including TGF-β1, a key regulator of cell signaling pathways that is involved in the development and progression of many diseases, including cancer.

ISOC1 has also been shown to play a role in the regulation of cellular processes that are important for maintaining tissue homeostasis. For example, ISOC1 has been shown to regulate the activity of cells involved in the production of extracellular matrix (ECM) components, such as collagen, which is important for maintaining tissue structure and integrity.

Despite these important functions, much is still not known about ISOC1. While there are several studies that have investigated the role of ISOC1 in various biological processes, more research is needed to fully understand its mechanisms of action and its potential as a drug target or biomarker.

One potential drug target for ISOC1 is its role in the regulation of cell division. ISOC1 has been shown to play a key role in the regulation of mitosis, and inhibition of ISOC1 has been shown to lead to increased cell division and the development of cancer. Therefore, ISOC1 may be an attractive target for drugs that are designed to inhibit its activity.

Another potential drug target for ISOC1 is its role in the regulation of cell signaling pathways. ISOC1 has been shown to interact with various signaling molecules, including TGF-β1, and inhibition of ISOC1 has been shown to reduce the activity of these molecules. Therefore, ISOC1 may be an attractive target for drugs that are designed to inhibit its activity and reduce the risk of cancer.

In addition to its potential drug targets, ISOC1 also has the potential to serve as a biomarker for various diseases. The regulation of cell division and signaling pathways by ISOC1 is a key aspect of many biological processes, and changes in these processes have been implicated in the development and progression of various diseases, including cancer. Therefore, ISOC1 may be an attractive biomarker for diseases that are characterized by changes in these processes.

Overall, ISOC1 is a protein that has important functions in various biological processes, including cell division and signaling pathways. While more research is needed to fully understand its mechanisms of action, its potential as a drug target or biomarker makes it an attractive target for further investigation.

Protein Name: Isochorismatase Domain Containing 1

The "ISOC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISOC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets